Abstract
[This corrects the article DOI: 10.18632/oncotarget.13531.].
Highlights
Hepatocellular carcinoma (HCC) has an extremely poor prognosis and is the fifth most common cancer in men and the ninth in women worldwide
MiR-34a and miR498 were further analyzed in an independent cohort of 106 HCC patients to determine whether they could serve as potential serum biomarkers to predict bone metastasis (BM)
The results of the univariate analyses revealed that serum miR-34a (P=0.002), serum miR-498 (P=0.038), tumor differentiation (P=0.011), tumor number (P=0.035), vascular invasion (P=0.005), and Barcelona Clinic Liver Cancer (BCLC) stage (P=0.002) were risk factors for BM in HCC patients (Table 1)
Summary
Hepatocellular carcinoma (HCC) has an extremely poor prognosis and is the fifth most common cancer in men and the ninth in women worldwide. It is the second leading cause of cancer death in men and the sixth in women worldwide [1]. Bone is destroyed by osteoclasts, which can cause pathological fractures, severe pain, and other nerve compression syndromes [5]. If we can identify biomarkers to predict BM in HCC patients, we could take measures to reduce the probability that BM will develop and potentially enhance the quality of life for HCC patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
